Harjianti Tutik, Fachruddin Andi, Minhajat Rahmawati, Saleh Sahyuddin, Bayu Dimas
Division of Hematology and Medical Oncology, Department of Internal Medicine, Medical Faculty Hasanuddin University, South Sulawesi, Indonesia.
Caspian J Intern Med. 2023 Summer;14(3):479-484. doi: 10.22088/cjim.14.3.479.
Breast cancer is a form of cancer that typically affects females. In general, cancer is caused by an imbalance between oncogene and supressor gene factors, including immunity factors against cancer cells. This study aims to compare the levels of IL-2 between breast cancer patients and healthy women, and also compare the levels of IL-2 between HER-2 positive and HER-2 negative, ER/PR positive and ER/PR negative, and among different malignancy grades of breast cancer patients.
This is an observational study using case control method. We include 46 breast cancer patients and 40 healthy women. Blood samples were taken from 46 breast cancer patients (20 HER-2 negative and 26 HER-2 positive patients); 40 of them received hormonal status (29 ER/PR negative and 11 ER/PR positive patients); and from 46 breast cancer patients, 37 of them were divided into malignancy grade. The level of IL-2 was compared between cases and controls and also among the breast cancer patients with HER-2 negative and positive; ER/PR negative and positive; and breast cancer with low, moderate and high grade.
IL-2 level was higher in breast cancer patients than in controls (9.400 pg/mL and 3.990 pg/mL respectively, P=0.003). IL-2 level is significantly higher in the breast cancer cases with positive HER-2 compared to negative HER-2 expression (11.154pg/mL and 7.120pg/mL respectively, P=0.001. No association between ER/PR expression nor breast cancer grading with IL-2 level.
IL-2 level is higher in breast cancer patients, especially breast cancer patients with HER-2 positive expression.
乳腺癌是一种通常影响女性的癌症形式。一般来说，癌症是由癌基因和抑癌基因因素失衡引起的，包括针对癌细胞的免疫因素。本研究旨在比较乳腺癌患者与健康女性之间的白细胞介素-2（IL-2）水平，同时比较HER-2阳性和HER-2阴性、雌激素受体/孕激素受体（ER/PR）阳性和ER/PR阴性的乳腺癌患者之间的IL-2水平，以及不同恶性程度的乳腺癌患者之间的IL-2水平。
这是一项采用病例对照方法的观察性研究。我们纳入了46例乳腺癌患者和40名健康女性。从46例乳腺癌患者（20例HER-2阴性和26例HER-2阳性患者）中采集血样；其中40例接受了激素状态检测（29例ER/PR阴性和11例ER/PR阳性患者）；并且从46例乳腺癌患者中，将37例分为恶性程度等级。比较病例组与对照组之间以及HER-2阴性和阳性、ER/PR阴性和阳性的乳腺癌患者之间以及低、中、高等级乳腺癌患者之间的IL-2水平。
乳腺癌患者的IL-2水平高于对照组（分别为9400 pg/mL和3990 pg/mL，P = 0.003）。HER-2阳性的乳腺癌病例中IL-2水平显著高于HER-2阴性表达的病例（分别为11154 pg/mL和7120 pg/mL，P = 0.001）。ER/PR表达及乳腺癌分级与IL-2水平之间无关联。
乳腺癌患者，尤其是HER-2阳性表达的乳腺癌患者，IL-2水平较高。
